Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

PHASE3CompletedINTERVENTIONAL
Enrollment

163

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
ADHD
Interventions
DRUG

Methylphenidate Transdermal System

One of 4 doses of the MTS transdermal patch over the same duration of wear for approximately 6 months

Trial Locations (32)

Unknown

Melmed Center, Scottsdale

Bay Area Research Institute, Lafayette

Elite Clinical Trials Inc., Wildomar

Sarkis Clinical Trials, Gainsville

Miami Research Associates, South Miami

Northwest Behavioral Research Ctr, Roswell

Mountain West Clinical Trials, LLC, Eagle

Vince and Associates Clinical Research, Overland Park

Shire Clinical Research Site, Lexington

Four Rivers Clinical Research, Inc., Paducah

Rochester Center for Behavioral Medicine, Rochester Hills

Clinical Neurophysiology Services, PC, Troy

CRI Worldwide, Clementon

Triangle Neuropsychiatry, Durham

Dakota Clinic/Innovis Health, Fargo

Odyssey Research, Minot

University Hospitals Case Medical Center, Cleveland

Oregon center for Clinical Investigations, Inc., Eugene

OCCI, Inc, Portland

Shire Clinical Research Site, Media

CRI Worldwide, Philadelphia

Rhode Island Hospital, Providence

CNS Healthcare, Memphis

FutureSearch Trials, Austin

Claghorn-Lesem Research, Ltd., Bellaire

Westex Clinical Investigations, Lubbock

Cerebral Research, LLC, San Antonio

Vermont Clinical Study Center, Burlington

NeuroScience, Inc., Herndon

Adolescent Health Center, Midlothian

Northwest Clinical Research Center, Friday Harbor

Eastside Therapeutic Resource, Kirkland

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Noven Therapeutics

INDUSTRY